Abstract
Purpose: This study aimed to retrospectively evaluate the overall survival and prognostic factors of patients treated using microballoon-occluded transarterial chemoembolization (B-TACE) with miriplatin for hepatocellular carcinoma (HCC).
Materials and Methods: Thirty-seven patients (23 men and 14 women; mean age, 74.1 years; Barcelona Clinic Liver Cancer stage A:21, B:10, C:6; first TACE, 17) treated using B-TACE with miriplatin were retrospectively analyzed. Overall survival and progression-free survival were analyzed using Kaplan-Meier methods, and a multivariate analysis was performed to identify prognostic factors. Side effects were analyzed on the basis of the National Cancer Institute's Common Terminology Criteria for Adverse Events (ver. 4.0).
Results: The 1-, 2-, and 3-year survival rates were 89.2% (95% confidence interval [CI], 74.5-95.9%), 67.3% (95% CI, 50.7-80.4%), and 60.9% (95% CI, 44.1-75.4%), respectively. The median survival time was 3.6 years. The median progression-free survival time was 8 months. Balloon increase (increased tumor stain under balloon occlusion; hazard ratio, 3.17; 95% CI, 1.135-11.201; P = 0.027) was the only factor significantly associated with overall survival on the multivariate analysis. No deaths occurred, but grade 2 cholecystitis requiring conservative treatment developed in 2 patients (4.8%). No adverse events over grade 3 occurred.
Conclusion: B-TACE with miriplatin was associated with comparable tumor control and overall survival without severe adverse events in patients with HCC. Balloon increase was the only factor significantly associated with overall survival.
